Glaukos Says Phase 4 Trial of iDose TR Meets Primary Efficacy Endpoint

MT newswire2026/10/09 11:28

07:28 AM EDT, 10/09/2026 (MT Newswires) -- Glaukos (GKOS) said Friday that topline results from a phase 4 clinical trial evaluating iDose TR in patients with open-angle glaucoma or ocular hypertension met its primary efficacy endpoint. The company said iDose TR showed statistically significant superiority in reducing mean diurnal intraocular pressure when administered along with cataract surgery, compared with cataract surgery alone. The company said iDose TR also demonstrated a favorable safety profile through three months, with no treated-related adverse events of corneal endothelial cell loss or cystoid macular edema, and no serious corneal adverse events. Shares of Glaukos were up more than 1% pre-bell Friday.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Sun Machinery CEO Park Kyung-hee Raises Stake to 8.40% From 8.31%

Bitget•2026/11/09 05:37

The central bank has increased its gold reserves for 24 consecutive months, with October’s increase hitting a record high for the period.

新浪财经•2026/11/09 05:37

Trader Gu Jingci: November 9 Bitcoin/Ethereum Trading Strategy and Market Analysis

AiCoin•2026/11/09 05:35

Dow Jones Top Energy Headlines at 12 AM ET: Oil Futures Slide As Market Holds Out Hopes for Middle East Diplomacy | Energy ...

Dow Jones•2026/11/09 05:00